Published Studies Related to Boniva Injection (Ibandronic Acid)
Well-designed clinical trials related to Boniva Injection (Ibandronic Acid)
Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. [2006]
Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). [2005.12]
Well-designed clinical trials possibly related to Boniva Injection (Ibandronic Acid)
Intravenous ibandronate or sodium-fluoride--a 3.5 years study on bone density and fractures in Crohn's disease patients with osteoporosis. [2011.06]
Bones and Crohn's: no benefit of adding sodium fluoride or ibandronate to calcium and vitamin D. [2011.01.21]
Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. [2010.10]
Treatment of osteoporosis after liver transplantation with ibandronate. [2010.07]
Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis. [2010.06]
[Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy]. [2010.06]
Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study. [2010.05]
The utility of changes in serum levels of C-terminal telopeptide of type I collagen in predicting patient response to oral monthly ibandronate therapy. [2010.04]
Efficacy and safety of monthly ibandronate in men with low bone density. [2010.04]
Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. [2010.03]
Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc analysis from DIVA. [2010.03]
Ibandronate increases cortical bone density in patients with systemic lupus erythematosus on long-term glucocorticoid. [2010]
Effects of intermittent intravenous ibandronate injections on bone quality and
micro-architecture in women with postmenopausal osteoporosis: the DIVA study. [2010]
The utility of changes in serum levels of C-terminal telopeptide of type I
collagen in predicting patient response to oral monthly ibandronate therapy. [2010]
Efficacy and safety of monthly ibandronate in men with low bone density. [2010]
Risk reduction of non-vertebral fractures with intravenous ibandronate: post-hoc
analysis from DIVA. [2010]
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. [2009.11]
Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. [2009.11]
Monthly ibandronate suppresses serum CTX-I within 3 days and maintains a monthly fluctuating pattern of suppression. [2009.09]
Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized double-blind, placebo-controlled trial. [2009.07]
Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. [2009.04]
Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. [2009.03]
Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study. [2009.01]
Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. [2009.01]
Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. [2008.10.01]
An open-label pilot trial of ibandronate for complex regional pain syndrome. [2008.10]
Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension. [2008.08]
Treatment of reduced bone density with ibandronate in dialysis patients. [2008.07]
Renal safety profiles of ibandronate 6 mg infused over 15 and 60 min: a randomized, open-label study. [2008.07]
Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). [2008.05]
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. [2008.03]
Bone turnover and bone collagen maturation in osteoporosis: effects of antiresorptive therapies. [2008.03]
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. [2008.01]
Cost effectiveness of ibandronate for the prevention of fractures in inflammatory bowel disease-related osteoporosis: cost-utility analysis using a Markov model. [2008]
Local peroperative treatment with a bisphosphonate improves the fixation of total knee prostheses: a randomized, double-blind radiostereometric study of 50 patients. [2007.12]
Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. [2007.11]
Oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases. [2007.07]
Rinsing morcellised bone grafts with bisphosphonate solution prevents their resorption. A prospective randomised double-blinded study. [2006.08]
Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. [2006.08]
Intravenous ibandronate does not affect time to renal function deterioration in patients with skeletal metastases from breast cancer: phase III trial results. [2006.07]
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. [2006.06]
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. [2006.05]
Modeling of serum C-telopeptide levels with daily and monthly oral ibandronate in humans. [2006.04]
Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. [2006.04]
Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. [2005.11]
Safety and tolerability of oral daily and intermittent ibandronate are not influenced by age. [2005.10]
Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. [2005.09]
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. [2005.08]
Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. [2005.06]
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. [2005.03]
Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. [2005.02]
[Ibandronate as a new therapeutic agent for osteoporosis.] [2005.01]
Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. [2004.10]
Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. [2004.10]
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. [2004.08]
Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. [2004.07]
Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. [2004.05]
Efficacy and safety of ibandronate given by intravenous injection once every 3 months. [2004.05]
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. [2004.05]
Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. [2004.03.22]
Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. [2004.03]
Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. [2004.01]
Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. [2003.10]
Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis. [2003.10]
Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. [2003.09]
Oral weekly ibandronate prevents bone loss in postmenopausal women. [2003.08]
Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. [2003.08]
Dose dependent effects on bone resorption and formation of intermittently administered intravenous ibandronate. [2003.07]
Oral ibandronate: changes in markers of bone turnover during adequately dosed continuous and weekly therapy and during different suboptimally dosed treatment regimens. [2003.06]
The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. [2003.04]
Therapy of osteoporosis in patients with Crohn's disease: a randomized study comparing sodium fluoride and ibandronate. [2003.03.15]
Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma. [2003.01]
Effect of bisphosphonates on cartilage turnover assessed with a newly developed assay for collagen type II degradation products. [2002.06]
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. [2002.05.01]
Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. [2002.01]
Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. [2001.10]
Effect of ibandronate on bone loss and renal function after kidney transplantation. [2001.07]
Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. [2000.05]
Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. [1999.10]
Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. [1999.03]
Bone densitometry: a new, highly responsive region of interest in the distal forearm to monitor the effect of osteoporosis treatment. [1999]
Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. [1998.11]
Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment. [1998.05]
Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. [1997.10]
Implementation of an osteoporosis research program with a mobile dual-energy X-ray absorptiometry unit: the Montana/Wyoming experience. [1997]
Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. [1997]
The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. [1996.11]
Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. [1996.01]
Other research related to Boniva Injection (Ibandronic Acid)
Renal function changes and NHS resource use in breast cancer patients with metastatic bone disease treated with IV zoledronic acid or oral ibandronic acid: a four-centre non-interventional study. [2010.03]
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.12]
Managing neoplastic bone disease with ibandronic acid: a preclinical and clinical data update. [2008.12]
Oral versus intravenous ibandronic acid: a comparison of treatment options for metastatic bone disease. [2008.05.27]
Eletriptan: a review of its use in the acute treatment of migraine. [2006]
Oral ibandronic acid. [2005.02]
Renal safety of intravenous ibandronic Acid in breast cancer patients with metastatic bone disease. [2003]
Other possibly related research studies
Use of intravenous bisphosphonates in osteoporosis. [2007.03]
The bisphosphonate ibandronate accelerates osseointegration of hydroxyapatite-coated cementless implants in an animal model. [2007.01]
[Therapeutic agents for disorders of bone and calcium metabolism: Ibandronate] [2007.01]
Population pharmacokinetics of ibandronate in Caucasian and Japanese healthy males and postmenopausal females. [2006.12]
|
